Vanta Bioscience Limited

BSE:540729 Stock Report

Market Cap: ₹268.1m

Vanta Bioscience Past Earnings Performance

Past criteria checks 0/6

Vanta Bioscience's earnings have been declining at an average annual rate of -62.5%, while the Life Sciences industry saw earnings growing at 25.3% annually. Revenues have been declining at an average rate of 14% per year.

Key information

-62.5%

Earnings growth rate

-62.3%

EPS growth rate

Life Sciences Industry Growth11.2%
Revenue growth rate-14.0%
Return on equity-111.9%
Net Margin-83.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Vanta Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:540729 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2446-38460
30 Jun 2472-31480
31 Mar 2497-23500
31 Dec 2397-34520
30 Sep 23103-45530
30 Jun 2386-55510
31 Mar 2363-65480
31 Dec 2269-45370
30 Sep 2275-25240
30 Jun 2288-12270
31 Mar 221001330
31 Dec 211012340
30 Sep 211014320
30 Jun 211014300
31 Mar 211014310
31 Dec 201115380
30 Sep 201215450
30 Jun 201318500
31 Mar 2014110550
31 Dec 1913910540
30 Sep 191379540
30 Jun 191318500
31 Mar 191247460
31 Dec 181105400
30 Sep 18953340
30 Jun 18682250
31 Mar 18400170

Quality Earnings: 540729 is currently unprofitable.

Growing Profit Margin: 540729 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 540729 is unprofitable, and losses have increased over the past 5 years at a rate of 62.5% per year.

Accelerating Growth: Unable to compare 540729's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 540729 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (38.1%).

Return on Equity

High ROE: 540729 has a negative Return on Equity (-111.93%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 08:12
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vanta Bioscience Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution